Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LYB | PRESS-RELEASE | neutral | 2/10 | LyondellBasell declared a quarterly dividend of $0.69 per share, payable June 8, 2026. This is a routine capital return | May 22, 2026 |
| BNTX | PRESS-RELEASE | neutral | 5/10 | BioNTech announced new clinical data for pumitamig (Phase 2/3 ROSETTA Lung-02 in 1L NSCLC) and gotistobart (Phase 2 PRES | May 22, 2026 |
| NGEN | PRESS-RELEASE | bearish | 6/10 | NervGen Pharma priced a $60M underwritten public offering of 24M common shares and warrants, with shares at $2.50 and wa | May 21, 2026 |
| LIMN | PRESS-RELEASE | bearish | 8/10 | Liminatus Pharma received a Nasdaq delisting notice after failing to regain compliance with the $50M market value of lis | May 21, 2026 |
| AAPG | PRESS-RELEASE | neutral | 4/10 | Ascentage Pharma announced that six abstracts from its clinical studies were selected for presentation at the 2026 ASCO | May 21, 2026 |
| BIIB | PRESS-RELEASE | bearish | 7/10 | Biogen and Denali announced that the Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease failed to meet it | May 21, 2026 |
| DNLI | PRESS-RELEASE | bearish | 7/10 | Denali Therapeutics and Biogen announced that the Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease fail | May 21, 2026 |
| CATX | PRESS-RELEASE | neutral | 4/10 | Perspective Therapeutics announced it will present updated data on three clinical-stage programs ([²¹²Pb]VMT-α-NET, [²¹² | May 21, 2026 |
| ZNTL | PRESS-RELEASE | bullish | 6/10 | Zentalis announced positive Phase 1b data for azenosertib plus paclitaxel in platinum-resistant ovarian cancer, with 39% | May 21, 2026 |
| AUTL | PRESS-RELEASE | neutral | 4/10 | Autolus Therapeutics released a post-hoc analysis of the Phase Ib/II FELIX study for ASCO, showing obe-cel achieved a 59 | May 21, 2026 |
| BDTX | PRESS-RELEASE | bullish | 8/10 | Black Diamond Therapeutics reported positive Phase 2 results for silevertinib in frontline NSCLC with EGFR non-classical | May 21, 2026 |
| AKTS | PRESS-RELEASE | bullish | 7/10 | Aktis reported first-in-human clinical imaging and dosimetry data for AKY-2519, a B7-H3-targeted miniprotein radioconjug | May 21, 2026 |
| REGN | PRESS-RELEASE | bullish | 6/10 | Regeneron announced positive Phase 1/2 LINKER-AL2 results for Lynozyfic (linvoseltamab) in second-line-plus systemic AL | May 21, 2026 |
| CMPX | PRESS-RELEASE | bullish | 7/10 | Compass Therapeutics announced a poster presentation at ASCO 2026 showing Phase 1 dose-escalation data for CTX-8371, a P | May 21, 2026 |
| OLMA | PRESS-RELEASE | bullish | 6/10 | Olema Oncology announced preliminary Phase 1 data for OP-3136, a KAT6 inhibitor, showing acceptable tolerability and ear | May 21, 2026 |
| LEGN | PRESS-RELEASE | bullish | 7/10 | Legend Biotech announced multiple ASCO 2026 presentations, including a rapid oral presentation of preliminary Phase 1 da | May 21, 2026 |
| CRDF | PRESS-RELEASE | neutral | 4/10 | Cardiff Oncology announced it will present updated Phase 2 data for onvansertib in RAS-mutated mCRC at ASCO on June 2, 2 | May 21, 2026 |
| NGEN | PRESS-RELEASE | bearish | 5/10 | NervGen Pharma announced an underwritten public offering of common shares and warrants (including pre-funded warrants) t | May 21, 2026 |
| TVGN | PRESS-RELEASE | neutral | 4/10 | Tevogen Bio announced a non-binding Letter of Intent to evaluate a potential transaction with a Management Services Orga | May 21, 2026 |
| TLSA | PRESS-RELEASE | bullish | 7/10 | Tiziana Life Sciences announced completion of patient enrollment in its Phase 2a INFORM-MS trial of intranasal foralumab | May 21, 2026 |
| NBTX | PRESS-RELEASE | bearish | 6/10 | Nanobiotix priced a global follow-on offering of 2,184,662 ordinary shares (including ADSs) and 345,099 pre-funded warra | May 21, 2026 |
| NBTX | PRESS-RELEASE | bearish | 6/10 | Nanobiotix priced a global follow-on offering raising ~$98.6M gross ($85M equivalent) via 2,184,662 ordinary shares (inc | May 21, 2026 |
| HCWB | PRESS-RELEASE | bearish | 6/10 | HCW Biologics priced a private placement of ~2.85M units at $1.405/unit, raising ~$4M in gross proceeds. The offering in | May 21, 2026 |
| AKTX | PRESS-RELEASE | bearish | 6/10 | Akari Therapeutics announced a private placement raising approximately $5.5 million through the sale of 1,470,588 ADSs a | May 21, 2026 |
| CGTX | PRESS-RELEASE | bullish | 6/10 | Cognition Therapeutics held a productive FDA meeting on May 20, 2026, to discuss Phase 2 SHIMMER study results for zervi | May 21, 2026 |
| COAG | PRESS-RELEASE | neutral | 5/10 | Hemab Therapeutics reported a Q1 2026 net loss of $22.7M ($23.98/share), widening from a $15.3M loss ($16.18/share) in Q | May 21, 2026 |
| IMMX | PRESS-RELEASE | bullish | 8/10 | Immix Biopharma announced that all four MRD-negative relapsed/refractory AL Amyloidosis patients from ASH 2025 have conv | May 21, 2026 |
| NBTX | PRESS-RELEASE | bearish | 6/10 | Nanobiotix has temporarily halted trading on Euronext Paris to finalize allocations and announce pricing for its previou | May 21, 2026 |
| RLAY | PRESS-RELEASE | bearish | 7/10 | Relay Therapeutics priced a $275M underwritten public offering of 22.9M shares at $12.00/share, representing approximate | May 20, 2026 |
| NBTX | PRESS-RELEASE | bearish | 5/10 | Nanobiotix launched a ~€75M (~$87M) global follow-on offering of ADSs and ordinary shares, plus pre-funded warrants. The | May 20, 2026 |